Drug:
Reaction: DERMATITIS ATOPIC
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26932714 |
US |
38 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 102 | 26932769 |
US |
64 | 1 |
Dermatitis atopic, Urticaria, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 103 | 26932770 |
US |
3 | 2 |
Dermatitis atopic, Rash macular, Rhinorrhoea, Therapeutic response shortened, |
||||
DUPILUMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, LORATADINE, |
||||
| 104 | 26932772 |
US |
20 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 105 | 26932777 |
US |
1 | |
Sleep disorder due to a general medical condition, Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 106 | 26932780 |
US |
2 | |
Dermatitis atopic, Rash, Skin hyperpigmentation, Dry skin, Pruritus, |
||||
DUPILUMAB, |
||||
| 107 | 26933040 |
US |
||
Rash, Dermatitis atopic, Device leakage, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 108 | 26933101 |
US |
44 | |
Dermatitis atopic, Pruritus, Skin discomfort, Formication, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 109 | 26933205 |
US |
2 | 2 |
Dermatitis atopic, Skin fissures, Erythema, Pruritus, Dry skin, |
||||
DUPILUMAB, |
||||
| 110 | 26933356 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 111 | 26933363 |
US |
67 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 112 | 26933403 |
US |
17 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 113 | 26933414 |
US |
43 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 114 | 26933420 |
US |
19 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 115 | 26933455 |
US |
53 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 116 | 26933480 |
US |
7 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 117 | 26933483 |
US |
1 | 2 |
Dermatitis atopic, Rash, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 118 | 26933493 |
US |
6 | 1 |
Bone pain, Dermatitis atopic, Rash, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 119 | 26933524 |
US |
2 | |
Pruritus, Sleep disorder due to a general medical condition, Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, |
||||
| 120 | 26933553 |
US |
8 | 2 |
Eczema, Dermatitis atopic, Dermatitis allergic, |
||||
DUPILUMAB, DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 121 | 26933564 |
US |
2 | |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 122 | 26933585 |
US |
20 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 123 | 26933587 |
US |
1 | |
Dermatitis atopic, Arthropod bite, |
||||
DUPILUMAB, |
||||
| 124 | 26933588 |
US |
60 | 1 |
Injection site pain, Dermatitis atopic, Inappropriate schedule of product administration, Product preparation issue, Pruritus, Dry skin, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 125 | 26933631 |
US |
1 | |
Dermatitis atopic, Asthma, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, AMLODIPINE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, BETAMETHASONE DIPROPIONATE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, |
||||
| 126 | 26933658 |
US |
2 | |
Dermatitis atopic, Dry skin, |
||||
DUPILUMAB, |
||||
| 127 | 26933660 |
US |
1 | |
Off label use, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 128 | 26933666 |
US |
5 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 129 | 26933687 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 130 | 26933688 |
US |
15 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 131 | 26933784 |
US |
6 | 2 |
Rash erythematous, Dermatitis atopic, Dermatitis allergic, Dyshidrotic eczema, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 132 | 26933808 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 133 | 26933823 |
US |
2 | |
Pruritus, Dermatitis atopic, Therapeutic response shortened, Inappropriate schedule of product administration, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 134 | 26933845 |
US |
6 | 1 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 135 | 26933994 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, SOMATROPIN, |
||||
| 136 | 26933996 |
US |
59 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 137 | 26934000 |
US |
2 | |
Tinea infection, Dermatitis atopic, |
||||
DUPILUMAB, LITHIUM CARBONATE, PRAZOSIN HYDROCHLORIDE, RISPERIDONE, |
||||
| 138 | 26926639 |
US |
1 | 1 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 139 | 26926906 |
US |
24 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 140 | 26927083 |
US |
2 | |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 141 | 26927250 |
US |
43 | 1 |
Pruritus, Skin fissures, Dry skin, Skin exfoliation, Dermatitis atopic, |
||||
DUPILUMAB, CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, ROFLUMILAST, |
||||
| 142 | 26927513 |
US |
70 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 143 | 26927719 |
US |
61 | 2 |
Dermatitis atopic, Wheezing, Cough, |
||||
DUPILUMAB, |
||||
| 144 | 26927756 |
US |
33 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 145 | 26928005 |
US |
49 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 146 | 26928376 |
EU |
76 | 1 |
Dermatitis atopic, |
||||
SULFAMETHOXAZOLE AND TRIMETHOPRIM, |
||||
| 147 | 26928414 |
US |
30 | 2 |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
| 148 | 26928417 |
US |
55 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 149 | 26928419 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 150 | 26928428 |
US |
9 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 151 | 26928437 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 152 | 26928438 |
US |
39 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 153 | 26928454 |
US |
42 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 154 | 26928636 |
US |
13 | 2 |
Eczema, Dermatitis atopic, Pruritus, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 155 | 26928799 |
US |
20 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 156 | 26928813 |
US |
8 | 2 |
Injection site pain, Dermatitis atopic, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 157 | 26928830 |
US |
15 | 2 |
Sleep disorder due to a general medical condition, Rash, Skin discomfort, Dermatitis atopic, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 158 | 26929080 |
JP |
53 | 1 |
Pruritus, Dermatitis atopic, Adrenocorticotropic hormone deficiency, |
||||
IPILIMUMAB, NIVOLUMAB, |
||||
| 159 | 26929244 |
US |
4 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 160 | 26929294 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 161 | 26929643 |
JP |
1 | |
Dermatitis atopic, |
||||
TOFACITINIB, |
||||
| 162 | 26929941 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 163 | 26929956 |
US |
27 | 2 |
Gastrointestinal disorder, Pain, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, SERTRALINE, |
||||
| 164 | 26929989 |
US |
90 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 165 | 26929996 |
US |
2 | |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 166 | 26930377 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, CALCIUM, FAMOTIDINE, ESOMEPRAZOLE MAGNESIUM, ERGOCALCIFEROL, EZETIMIBE, |
||||
| 167 | 26930380 |
US |
23 | 1 |
Urticaria, Ocular hyperaemia, Dermatitis atopic, Pruritus, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 168 | 26930385 |
US |
44 | 2 |
Dermatitis atopic, Eczema, |
||||
DUPILUMAB, |
||||
| 169 | 26930741 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 170 | 26930755 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 171 | 26921345 |
US |
2 | |
Skin irritation, Vision blurred, Dermatitis atopic, Dry eye, |
||||
DUPILUMAB, TRALOKINUMAB-LDRM, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, |
||||
| 172 | 26921495 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 173 | 26921497 |
US |
2 | |
Sleep disorder due to a general medical condition, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 174 | 26921510 |
US |
2 | |
Dermatitis atopic, Skin fissures, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 175 | 26921522 |
US |
1 | |
Rash pruritic, Product dose omission issue, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, INFLIXIMAB, |
||||
| 176 | 26921910 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 177 | 26922145 |
US |
22 | 2 |
Urticaria, Dry eye, Myalgia, Dermatitis atopic, Incorrect dose administered by device, |
||||
DUPILUMAB, |
||||
| 178 | 26922179 |
US |
1 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 179 | 26922420 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 180 | 26923046 |
US |
1 | |
Dermatitis atopic, Therapeutic product effect incomplete, |
||||
DUPILUMAB, |
||||
| 181 | 26923071 |
US |
1 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 182 | 26923514 |
JP |
||
Drug eruption, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 183 | 26923522 |
US |
56 | 2 |
Injection site pain, Dermatitis, Injection site swelling, Pruritus, Arthralgia, Peripheral swelling, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 184 | 26923749 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 185 | 26925416 |
US |
9 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 186 | 26925425 |
US |
9 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 187 | 26925780 |
US |
70 | |
Dermatitis atopic, Device malfunction, Incorrect dose administered, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 188 | 26926373 |
US |
47 | |
Pruritus, Pustule, Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 189 | 26915013 |
US |
57 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, ABATACEPT, ABATACEPT, ABATACEPT, GOLIMUMAB, |
||||
| 190 | 26915014 |
US |
42 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 191 | 26915025 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 192 | 26915249 |
US |
58 | |
Rash, Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 193 | 26915602 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, ESTRADIOL, ESTRADIOL GEL 0.1%, ESTRADIOL TRANSDERMAL, ESTRADIOL,, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, LISDEXAMFETAMINE DIMESYLATE, |
||||
| 194 | 26915946 |
US |
4 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 195 | 26916133 |
US |
38 | 2 |
Dermatitis atopic, Drug ineffective, |
||||
TRALOKINUMAB-LDRM, TRALOKINUMAB-LDRM, |
||||
| 196 | 26916305 |
US |
56 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 197 | 26916462 |
US |
27 | |
Nephrolithiasis, Acne, Xerosis, Angular cheilitis, Lip dry, Dermatitis atopic, |
||||
ISOTRETINOIN, |
||||
| 198 | 26916596 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 199 | 26917667 |
US |
32 | 1 |
Blister, Dermatitis atopic, |
||||
DUPILUMAB, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE, |
||||
| 200 | 26917687 |
US |
46 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30